# SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07662811/  
OnCo record `nct07662811` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of carboplatin, nab-paclitaxel and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.

## Summary

SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer is a phase 2/3, randomised interventional study registered as NCT07662811 by Shanghai Chest Hospital, with a registry enrolment figure of 396 participants, started 2026-06-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: SYHX2011; Carboplatin; Enlonstobart; Nab-Paclitaxel; Carboplatin; Tislelizumab. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR) for phase II; Progression Free Survival (PFS) for phase III. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced or metastatic squamous non-small cell lung cancer (Stage IIIB, IIIC, or IV according to the IASLC 9th Edition TNM Staging System), ineligible for radical surgery and/or radical radiotherapy". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07662811
- Phase: 2/3
- Setting: SYHX2011 in Combination With Carboplatin and Enlonstobart Versus Nab-Paclitaxel Plus Carboplatin and Tislelizumab as First-Line Therapy for Squamous Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase II/III Study
- Sponsor: Shanghai Chest Hospital
- Enrolled: 396

## Sources

- ClinicalTrials.gov NCT07662811: https://clinicaltrials.gov/study/NCT07662811

## Connected records

- cancers: [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07662811.json